RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds. RHB-204 is currently in Phase 3 for…
Consensus price target: $19,000.00 (+4439152.34% upside from $0.43)
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $286K | -96.44% | $-429K |
| 2024 | $8.04M | +23.17% | $-8.27M |
| 2023 | $6.53M | -89.43% | $23.92M |
Stock data for RDHL: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics